Logo image of CELU

CELULARITY INC-A (CELU) Stock Fundamental Analysis

NASDAQ:CELU - Nasdaq - US1511902041 - Common Stock - Currency: USD

1.68  -0.12 (-6.67%)

Fundamental Rating

1

CELU gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. CELU may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CELU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CELU has reported negative net income.
CELU had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CELU reported negative net income in multiple years.
CELU had a negative operating cash flow in each of the past 5 years.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

CELU's Return On Assets of -27.21% is fine compared to the rest of the industry. CELU outperforms 72.01% of its industry peers.
CELU has a Return On Equity of -202.85%. This is in the lower half of the industry: CELU underperforms 69.88% of its industry peers.
Industry RankSector Rank
ROA -27.21%
ROE -202.85%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

CELU has a better Gross Margin (64.20%) than 80.93% of its industry peers.
The Profit Margin and Operating Margin are not available for CELU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CELU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -10.65, we must say that CELU is in the distress zone and has some risk of bankruptcy.
CELU has a worse Altman-Z score (-10.65) than 75.22% of its industry peers.
A Debt/Equity ratio of 2.47 is on the high side and indicates that CELU has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.47, CELU is doing worse than 83.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.47
Debt/FCF N/A
Altman-Z -10.65
ROIC/WACCN/A
WACC9.18%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.19 indicates that CELU may have some problems paying its short term obligations.
With a Current ratio value of 0.19, CELU is not doing good in the industry: 97.15% of the companies in the same industry are doing better.
A Quick Ratio of 0.14 indicates that CELU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.14, CELU is doing worse than 97.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.14
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.54% over the past year.
Looking at the last year, CELU shows a very strong growth in Revenue. The Revenue has grown by 225.94%.
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.29%
Revenue 1Y (TTM)225.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%145.54%

3.2 Future

CELU is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.54% yearly.
Based on estimates for the next years, CELU will show a very strong growth in Revenue. The Revenue will grow by 48.52% on average per year.
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%

3.3 Evolution

CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELU. In the last year negative earnings were reported.
Also next year CELU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

CELU's earnings are expected to decrease with -9.54% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CELU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (2/21/2025, 8:07:08 PM)

1.68

-0.12 (-6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-31 2024-12-31/amc
Earnings (Next)07-28 2025-07-28/amc
Inst Owners14.98%
Inst Owner Change-99.99%
Ins Owners16.73%
Ins Owner Change0.21%
Market Cap37.77M
Analysts82.86
Price TargetN/A
Short Float %1.74%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF N/A
P/OCF N/A
P/B 2.19
P/tB 122.22
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.14
BVpS0.77
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.21%
ROE -202.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.2%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 2.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.21%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.14
Altman-Z -10.65
F-Score5
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)56.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)25.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.29%
EPS Next Y-62.86%
EPS Next 2Y-9.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)225.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%145.54%
Revenue Next Year-68.68%
Revenue Next 2Y2.27%
Revenue Next 3Y3.99%
Revenue Next 5Y48.52%
EBIT growth 1Y-212.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y91.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.21%
OCF growth 3YN/A
OCF growth 5YN/A